Federal contract award

75N93023C00013

MITIGATION OF MULTI-ORGAN DELAYED EFFECTS OF ACUTE RADIATION EXPOSURE (DEARE) WITH ACE-INHIBITOR LISINOPRIL

Research the contractorView USAspending sourceSave to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

FieldReported value
AgencyDepartment of Health and Human Services
OfficeNATIONAL INSTITUTES OF HEALTH NIAID
NAICS541714 — Research and Development in Biotechnology (except Nanobiotechnology)
PSCAN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
Parent award / vehicleNot reported
Set-asideNO SET ASIDE USED.
Pricing typeCOST NO FEE
Obligations$3.3M
Current contract value$3.3M
Potential contract value / ceiling$3.3M
Start dateJul 1, 2023
Current end dateJun 30, 2027
Potential end dateJun 30, 2027
Latest award activityJul 16, 2026
Source loadedSep 26, 2026

Funding and modification history

Showing the latest 11 of 11 loaded transactions. Negative values are deobligations.

DateModificationObligation changeDescription
Jul 16, 2026P00010$0EO 14398
Mar 18, 2026P00009$0MITIGATION OF MULTI-ORGAN DELAYED EFFECTS OF ACUTE RADIATION EXPOSURE (DEARE) WITH ACE-INHIBITOR LISINOPRIL
Aug 5, 2025P00008$177.8KMITIGATION OF MULTI-ORGAN DELAYED EFFECTS OF ACUTE RADIATION EXPOSURE (DEARE) WITH ACE-INHIBITOR LISINOPRIL
Jul 21, 2025P00007$999.6KMITIGATION OF MULTI-ORGAN DELAYED EFFECTS OF ACUTE RADIATION EXPOSURE (DEARE) WITH ACE-INHIBITOR LISINOPRIL
Apr 28, 2025P00006$0MITIGATION OF MULTI-ORGAN DELAYED EFFECTS OF ACUTE RADIATION EXPOSURE (DEARE) WITH ACE-INHIBITOR LISINOPRIL
May 31, 2024P00005$998.3KMITIGATION OF MULTI-ORGAN DELAYED EFFECTS OF ACUTE RADIATION EXPOSURE (DEARE) WITH ACE-INHIBITOR LISINOPRIL
May 13, 2024P00004$0MITIGATION OF MULTI-ORGAN DELAYED EFFECTS OF ACUTE RADIATION EXPOSURE (DEARE) WITH ACE-INHIBITOR LISINOPRIL
Nov 2, 2023P00003$0MITIGATION OF MULTI-ORGAN DELAYED EFFECTS OF ACUTE RADIATION EXPOSURE (DEARE) WITH ACE-INHIBITOR LISINOPRIL
Aug 22, 2023P00002$100.0KMITIGATION OF MULTI-ORGAN DELAYED EFFECTS OF ACUTE RADIATION EXPOSURE (DEARE) WITH ACE-INHIBITOR LISINOPRIL
Aug 14, 2023P00001$0MITIGATION OF MULTI-ORGAN DELAYED EFFECTS OF ACUTE RADIATION EXPOSURE (DEARE) WITH ACE-INHIBITOR LISINOPRIL
Jun 29, 20230$1000.0KMITIGATION OF MULTI-ORGAN DELAYED EFFECTS OF ACUTE RADIATION EXPOSURE (DEARE) WITH ACE-INHIBITOR LISINOPRIL

Estimated positioning window

Nov 1, 2026 – Jan 30, 2027

Recompete signal:
80/100

Why this recompete signal

Contract timing and recorded acquisition signals at the time of calculation.

Stored score: 80/100. Available recorded signals: 75 points.

Contract end 2027-06-30 (241 days from calculation)
+35 points
103 historical awards in this buyer and category group
+15 points
11 recorded award transactions
+10 points
Latest award action: 2026-07-16
+5 points
Parent award identifier recorded
+0 points
Solicitation identifier recorded
+10 points
Linked official forecast
+0 points
Calculated on
2026-11-01 10:17:53.997580+00:00

The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.

Rule-based research score; it does not measure your chance of winning.

This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.

USAspending award record

. Rule-based research score; positioning dates are estimates.

Recompete score calculated Nov 1, 2026.

Buyer contacts from matching notices

Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.

ContactRolePublished contact methodsEvidenceSource date
Anuj PatelContactanuj.patel@nih.govSourceJan 28, 2022
Liem NguyenContactliem.nguyen@nih.govSourceJan 28, 2022

Research next steps

  1. Check the linked forecast or SAM for a confirmed solicitation and current timing.
  2. Check the stated set-aside against the solicitation and current certifications.
  3. Review the award scope and buyer evidence before making a bid/no-bid decision.